QI
SYRS

QS Investors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

QS Investors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$349K Hold
6,400
– – ﹤0.01% 889
2021
Q1 		$479K Buy
6,400
+3,940
+160% +$409K 0.01% 812
2020
Q4 		$267K Buy
+2,460
New +$224K ﹤0.01% 1032

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

QS Investors's SYRS Position: Q2 2021 in Review

QS Investors held its Syros Pharmaceuticals, Inc. Common Stock (SYRS) position steady in Q2 2021 at 6,400 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #889.

QS Investors first reported a position in SYRS in Q4 2020 and has held it in 3 quarters since. The position peaked at $479K in Q1 2021. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • QS Investors held 6,400 shares of Syros Pharmaceuticals, Inc. Common Stock worth $349K as of Q2 2021.
  • QS Investors left its Syros Pharmaceuticals, Inc. Common Stock share count unchanged in Q2 2021.
  • Syros Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #889 holding.
  • QS Investors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and has held it in 3 quarters since.
  • QS Investors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $479K in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.